{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"Estimations were done separately in each treatment arm; the difference between treatments was not calculated.","pValue":"0.428","pValueComment":"A one-sided significance level of 0.10 will be considered for the test.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"}]}],"title":"Combined total PR + CR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"ORR is defined as the proportion of patients who have achieved Complete Response (CR) - disappearance of all target lesions or Partial Response (PR) - \\>=30% decrease in the sum of the longest diameter of target lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; Overall Response (OR) = CR + PR.","groups":[{"description":"Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV\n\nGlycosylated Recombinant Human Interleukin-7: Given IM","id":"OG000","title":"Group 1 (CYT107, Atezolizumab)"},{"description":"Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV","id":"OG001","title":"Group 2 (Atezolizumab)"},{"description":"Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV\n\nGlycosylated Recombinant Human Interleukin-7: Given IM","id":"OG002","title":"Safety Run in Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}